**国家药监局启动血液制品生产智慧监管三年行动计划**
中新网北京消息，5月31日电 据国家药监局网站最新消息，国家药监局党组书记、局长李利在近日召开的会议中，重点研究并部署实施了《血液制品生产智慧监管三年行动计划（2024—2026年）》。该计划旨在通过智慧化手段强化血液制品生产监管，确保公众健康安全。
随着科技的快速发展，智慧监管成为新趋势。此次会议强调，在接下来的三年里，将全面推动血液制品生产信息化管理，利用现代技术手段实现生产流程的实时监控与数据分析。预计至2026年底，基本完成血液制品生产智慧监管体系的构建，大幅增强监管效能，确保血液制品的质量与安全。
该行动计划的实施，标志着我国血液制品监管迈上新台阶。国家药监局将联合相关部门和企业，共同推进血液制品产业的智慧化转型，为公众提供更加安全、高效的血液制品。
此次会议还就如何具体实施该行动计划进行了深入探讨和部署，以确保各项措施的有效落实。业内专家和人士对此表示高度关注和期待。
英语如下：
News Title: “National Medical Products Administration Initiates Three-Year Smart Supervision Plan for Blood Products to Ensure Full Informationalization by 2026”
Keywords: Smart Supervision of Blood Products, Three-Year Action Plan, Information Technology-Based Supervision
News Content: **National Medical Products Administration Initiates Smart Supervision Action Plan for Blood Products Production**
Beijing, China News Service, May 31 – According to the latest news from the National Medical Products Administration (NMPA) website, Li Li, the secretary of the Party Leadership Group and director of the NMPA, highlighted and deployed the implementation of the “Three-Year Smart Supervision Action Plan for Blood Products Production (2024-2026)” at a recent meeting. The plan aims to strengthen the supervision of blood products production through smart technologies to ensure public health and safety.
With the rapid development of technology, smart supervision has become a new trend. The meeting emphasized that in the next three years, comprehensive promotion of information technology management in blood products production will be carried out, utilizing modern technological means to achieve real-time monitoring and data analysis of the production process. It is expected that by the end of 2026, the construction of a smart supervision system for blood products production will be basically completed, significantly enhancing supervision efficiency and ensuring the quality and safety of blood products.
The implementation of this action plan marks a new level in the supervision of blood products in China. The NMPA will work with relevant departments and enterprises to jointly promote the smart transformation of the blood products industry, providing the public with safer and more efficient blood products.
The meeting also conducted thorough discussions and deployments on how to implement the action plan to ensure effective implementation of various measures. Industry experts and insiders have expressed high concern and expectations for this plan.
【来源】http://www.chinanews.com/cj/2024/05-31/10226475.shtml
Views: 3